文献速递系统性红斑狼疮其他结缔组织病

系统性红斑狼疮中血小板尺寸减小与血小板活化及抗磷脂综合征相关

Decreased platelet size is associated with platelet activation and anti-phospholipid syndrome in systemic lupus erythematosus.
PubMed 文献 · Rheumatology (Oxford) · 2017-01-01

该研究分析148例SLE患者、79名健康对照和40例疾病对照的新鲜血样,发现SLE患者血小板尺寸较健康对照减小(P=0.003),且尺寸减小与血小板活化(微粒形成、致密颗粒释放血清素)相关,并与继发性APS独立相关(校正传统心血管危险因素后P=0.01,OR 3.58)。

要点

  • SLE患者血小板尺寸较健康对照减小(P=0.003)。
  • 血小板尺寸减小与微粒形成及致密颗粒释放血清素相关。
  • 血小板尺寸减小与继发性APS相关,校正心血管危险因素后仍显著。

核心结论

  • SLE患者血小板尺寸减小,且与血小板活化及APS相关,未来需研究其机制及对疾病并发症的预测价值。

研究设计与样本

  • 研究纳入148例SLE患者、79名健康志愿者和40例疾病对照,采用流式细胞术、ELISA和细胞计数分析新鲜血样的血小板尺寸与活化。

主要发现

  • SLE患者血小板尺寸较健康对照减小(P=0.003)。
  • SLE中血小板尺寸减小与微粒形成相关(P<0.0001,r=-0.46),与致密颗粒释放血清素相关(P<0.001,r=0.57)。
  • 有aCL的SLE患者血小板尺寸减小(P=0.02),aCL在体外使血小板尺寸减小(P=0.007)。
  • 与一般人群不同,SLE中血小板尺寸增大与心血管疾病无关。
  • 血小板尺寸减小与继发性APS相关,校正传统心血管危险因素后P=0.01,OR 3.58。

临床怎么用

  • 在SLE患者中关注血小板尺寸减小,可能提示血小板活化及继发性APS风险。
  • 对SLE患者评估APS时,血小板尺寸减小或可作为辅助线索,但需进一步验证。

局限性

  • 原文未明确报告研究设计类型及样本量以外的局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: . SLE is an autoimmune disease with increased cardiovascular morbidity and platelet activation. In the general population, increased platelet size predicts platelet reactivity and cardiovascular disease. The aim of this study was to investigate whether platelet size related to platelet activation and cardiovascular disease in SLE. METHODS: . Fresh blood samples from SLE patients ( n = 148), healthy volunteers ( n = 79) and disease controls ( n = 40) were analysed for platelet size and activation by flow cytometry, ELISA and cell count. Associations to manifest cardiovascular disease, venous thrombosis and APS were adjusted for traditional cardiovascular risk factors using logistic regression analysis. RESULTS: . SLE patients had decreased platelet size as compared with healthy controls ( P = 0.003). In SLE, decreased platelet size was related to increased platelet activation, in particular microparticle formation ( P < 0.0001, r = -0.46) and release of serotonin from dense granules ( P < 0.001, r = 0.57). SLE patients with aCL had decreased platelet size ( P = 0.02) and aCL decreased platelet size in vitro ( P = 0.007). In contrast to the general population, increased platelet size was not associated with cardiovascular disease. Instead, decreased platelet size was associated with secondary APS, even after adjusting for traditional cardiovascular risk factors ( P = 0.01, odds ratio 3.58). CONCLUSION: . Platelet size is decreased in SLE patients and associated with microparticle formation and APS. Future studies are needed to determine the underlying mechanism(s) as well as the potential predictive value of small platelets for disease complications in SLE.

来源:Rheumatology (Oxford),查看原文。版权归原作者所有。

引用

  1. Lood C, Tydén H, Gullstrand B, et al. Decreased platelet size is associated with platelet activation and anti-phospholipid syndrome in systemic lupus erythematosus. Rheumatology (Oxford). 2017. PMID: 28031442. doi:10.1093/rheumatology/kew437

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。